Does Portal-Superior Mesenteric Vein Invasion Still Indicate Irresectability for Pancreatic Carcinoma?
- 543 Downloads
Pancreatic carcinoma frequently infiltrates the portal vein or the superior mesenteric vein; pancreatectomy combined with portal vein/superior mesenteric vein resection represents a potentially curative treatment in these cases but is still a controversial procedure.
After performing a computerized Medline search, 12 series published during the last 8 years were selected, enrolling 399 patients who underwent pancreatectomy combined with portal vein/superior mesenteric vein resection for pancreatic carcinoma. Data were examined for information about indications, operation, adjuvant therapies, histopathology of resected specimens, perioperative results, and survival. Also, previous literature regarding the issue was extensively reviewed.
Operative mortality and postoperative complication rates ranged from 0 to 7.7% and 16.7% to 54%, respectively. Median survival varied from 13 to 22 months; 5-year survival rate ranged from 9% to 18%.
The current literature suggests that portal vein/superior mesenteric vein resection combined with pancreatectomy is a safe and feasible procedure that increases the number of patients who undergo curative resection and, therefore, provides important survival benefits to selected groups of patients. This procedure should always be considered in case of suspected tumor infiltration of portal/superior mesenteric vein to achieve clear resection margins, in the absence of other contraindications for resection.
KeywordsPortal Vein Pancreatic Carcinoma National Comprehensive Cancer Network National Comprehensive Cancer Network Superior Mesenteric Vein
- 23.Adham M, Mirza DF, Chapuis F et al. Results of vascular resections during pancreatectomy from two European centres: an analysis of survival and disease-free survival explicative factors. HBP (Oxford). 2006;8:465–73.Google Scholar
- 30.Lygidakis NJ, Singh G, Bardaxoglou E, et al. Mono-bloc total spleno-pancreaticoduodenectomy for pancreatic head carcinoma with portal-mesenteric venous invasion. A prospective randomized study. Hepatogastroenterology. 2004;51:427–33.Google Scholar
- 37.Sindelar WF. Clinical experience with regional pancreatectomy for adenocarcinoma of the pancreas. Arch Surg. 1989;1124:127–32.Google Scholar
- 38.Yeo CJ, Cameron JL, Lillemoe KD et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. Part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg. 2002;236:355–68.PubMedCrossRefGoogle Scholar
- 54.Soriano A, Castells A, Ayuso C et al. Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am J Gastroenterol. 2004;99:492–501.PubMedCrossRefGoogle Scholar
- 55.Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. Am J Roentgenol. 1997;168:1439–43.Google Scholar
- 82.National Cancer Institute, Pancreatic Cancer Treatment. http://www.cancer.gov/cancertopics/pdq/treatment/pancreatic/HealthProfessional. Accessed 7 Sept 2008.
- 83.National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology. Pancreatic adenocarcinoma. http://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf. Accessed 7 Sept 2008.